What is the recommended procedure for rapid plasma reagin (RPR) testing and subsequent management of syphilis?

Rapid Plasma Reagin (RPR) Testing: Procedure and Management

RPR testing should be performed using either manual card dilution or automated latex turbidimetric methods, with results reported quantitatively, and used in combination with treponemal testing (FTA-ABS or TP-PA) for diagnosis—never use RPR alone, as it is a nontreponemal test that can yield false positives.

Diagnostic Testing Approach

Initial Testing Strategy

• RPR cannot diagnose syphilis by itself—it must be paired with a treponemal test (FTA-ABS or TP-PA) 1, 2
• Nontreponemal tests (RPR/VDRL) detect antibodies that correlate with disease activity
• Treponemal tests confirm the presence of T. pallidum infection
• False-positive nontreponemal results occur with various medical conditions, making dual testing mandatory 1

Quantitative Reporting Requirements

• All RPR results must be reported quantitatively (e.g., 1:16,1:32) 1
• A 4-fold change in titer equals a 2-dilution change (e.g., 1:16 to 1:4 or 1:8 to 1:32) and represents clinically significant change 1
• Sequential tests should use the same method (RPR vs VDRL) and preferably the same laboratory 1
• RPR titers are often slightly higher than VDRL titers—results cannot be directly compared 1

Testing Methodology

Manual vs Automated Methods

• Automated latex turbidimetric RPR shows strong correlation with manual card tests (r=0.931) 3
• Automated methods are faster, handle more specimens, and eliminate interpersonal variation 3
• For diagnosis: automated RPR ≥6.0 units has 92.5% PPV and 99.4% NPV when manual titer is ≥1:8 3
• For treatment monitoring: 76.54% decrement in automated RPR corresponds to 4-fold decline in manual test 3

Timing Considerations

Critical caveat: RPR titers can increase for up to 14 days after treatment initiation 4

• 20% of early syphilis patients show titer increases immediately post-treatment 4
• If diagnosis and treatment dates differ, repeat RPR on treatment day—even 1-3 days apart, 5.7% show ≥4-fold changes; at 10-14 days, 26.2% change 5
• This affects baseline determination for monitoring treatment response

Screening Recommendations by Population

Pregnancy (Universal Screening)

• Screen all women in early pregnancy 2
• High-prevalence areas or high-risk patients: repeat at 28 weeks AND at delivery 2
• If prenatal care utilization is poor: screen and treat immediately when pregnancy diagnosed 2
• Any stillbirth after 20 weeks mandates maternal syphilis testing 2
• No infant should leave hospital without documented maternal serologic status 2

HIV-Infected Persons

• Screen at least annually for all sexually active HIV-infected persons 6
• Every 3-6 months for those with: multiple partners, unprotected intercourse, methamphetamine use, or sex with drug use 6
• HIV infection can cause atypical serologic results (unusually high, low, or fluctuating titers), but tests remain accurate for most patients 1, 2

High-Risk Populations

• Substance use disorder (51.9% of syphilis cases in urban settings) 7
• Unstable housing (42.8% of cases) 7
• Men who have sex with men with repeated exposures 8

Treatment Monitoring

Follow-Up Testing Schedule

Standard follow-up: Clinical and serologic evaluation at 6 and 12 months after treatment 1

HIV-infected patients with latent syphilis: More intensive monitoring at 6,12,18, and 24 months 2

Defining Treatment Success

• Serologic cure: ≥4-fold decline in nontreponemal titer (2-dilution decrease) 1
• With automated RPR: ≥75% reduction from baseline 3
• Median time to seroreversion (non-reactive): 235 days, achieved in only 42.3% of cases 8

Treatment Failure Indicators

Re-treat if any of the following occur 1:

• Clinical symptoms persist or recur
• Sustained 4-fold increase in titer compared to baseline
• Failure to achieve 4-fold decline within 6 months (primary/secondary syphilis) 1
• Failure to achieve 4-fold decline within 12-24 months (latent syphilis) 2

When treatment failure suspected:

1. Perform CSF examination to exclude neurosyphilis 1
2. Re-evaluate for HIV infection 1
3. Re-treat with benzathine penicillin G 2.4 million units IM weekly × 3 weeks if CSF normal 1

Serofast State

Definition and Prevalence

• Serofast: Failure to achieve 4-fold decline after stage-appropriate therapy 9
• Occurs in substantial proportion of patients regardless of HIV status 9
• Predictors of remaining serofast 9, 8:
  • Older age
  • Earlier syphilis stage (paradoxically less likely to serorevert)
  • Lower baseline nontreponemal titers
  • HIV infection
  • Late latent syphilis
  • Subsequent syphilis reinfection

Management

• Serofast patients with normal CSF and no symptoms do not require additional treatment 9
• Consider CSF examination if titers remain elevated (≥1:32) or clinical concerns arise 10
• Limited data support additional antibiotic courses for asymptomatic serofast patients 9

Special Testing Situations

Neurosyphilis Evaluation

Indications for CSF examination before treatment 10:

• Neurologic or ophthalmic signs/symptoms
• Other evidence of active tertiary syphilis (aortitis, gumma, iritis)
• Treatment failure
• HIV infection with late latent or unknown duration syphilis
• Serum nontreponemal titer ≥1:32 (unless infection <1 year)
• Non-penicillin therapy planned (unless infection <1 year)

CSF testing specifics:

• VDRL-CSF is standard—reactive result (without blood contamination) is diagnostic 2, 10
• CSF leukocyte count >5 WBC/mm³ suggests active neurosyphilis 2, 10
• CSF FTA-ABS is more sensitive but less specific than VDRL-CSF 2
• CSF TPPA at titer ≥1:640 has specificity similar to CSF VDRL 9

Limitations in Specific Populations

HIV-infected patients with repeated exposures 8:

• Slow RPR decay post-therapy makes assessing re-infection difficult
• Seroreversion significantly less likely with HIV infection (p=0.02)
• Lower likelihood of documented cure with subsequent syphilis episodes

Sensitivity by stage 11:

• Primary/secondary untreated: 95-100%
• Early latent: 82-100%
• Late latent: 61-75%
• Treated syphilis: 66-75% (significantly lower)

Common Pitfalls to Avoid

1. Never use RPR alone for diagnosis—always confirm with treponemal test 1
2. Don't compare RPR and VDRL titers directly—they're not interchangeable 1
3. Don't use different labs or methods for serial monitoring—this introduces variability 1
4. Don't assume treatment failure if titers increase in first 2 weeks—this is physiologic 4
5. Don't rely solely on RPR for diagnosing re-infection in high-risk populations—consider clinical context 8
6. Don't use treponemal test titers to monitor treatment—they remain positive for life in most cases 1
7. Recognize that previously treated patients may have persistently low positive RPR—this is "serofast reaction," not active disease 1